News & Comments- Prohost Biotech - Exclusive Biotech Research

Category: News & Comments

Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

Reata Pharmaceuticals Announcements Reata Pharmaceuticals ( RETA ) announced that the abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held...

October 21, 2021

TRxADE HEALTH Subsidiary, Bonum Health, Signed a Telemedicine Service Distribution Deal with Big Y Pharmacy. See Also: Innate Pharma

TRxADE HEALTH Inc TRxADE HEALTH Inc ( MEDS ) is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S.. The firm operates the TRxADE...

July 1, 2021

INmune Bio: A Novel Approach Towards Treating Alzheimer's Disease

Alzheimer's Disease Alzheimer’s Disease has proven very difficult to treat through many of the trials’ attempts by both small and large biotechnology and biopharmaceutical companies. Analysts and investors are skeptical about all promised successes in defeating this disease. However, knowing...

July 14, 2020

Why Celldex Therapeutics Stock is Soaring

Celldex Therapeutics is Soaring Celldex Therapeutics ( CLDX ) stock soared following the firm’s announcement of updated data from its ongoing, open-label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, which are...

July 11, 2021

Gilead Sciences and Merck Initiate Phase 2 Study Evaluating Lenacapavir and Islatravir for HIV-1

Gilead Sciences and Merck Collaboration to Develop Long-Acting HIV Treatment Gilead Sciences ( GILD ) and Merck ( MRK ) announced the start of a Phase 2 clinical study evaluating an investigational, once-weekly oral combination treatment regimen of islatravir and...

October 26, 2021

Jazz Pharmaceuticals: A New FDA Approval

People living with narcolepsy who develop cataplexy and excessive daytime sleepiness have a new treatment called Xywav, from Jazz Pharmaceuticals. Jazz Pharmaceuticals NEWS On July 21, 2020 the U.S. FDA approved Jazz Pharmaceuticals’ ( JAZZ ) product Xywav™ (calcium, magnesium, potassium...

July 22, 2020

No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences Lead Drug Candidate

Cassava Science: Journal of Neuroscience Review Shows No Evidence of Data Manipulation Cassava Sciences ( SAVA ) has been informed by the Journal of Neuroscience that there is no evidence of data manipulation in an article it published in July 2012...

November 4, 2021

Intellia Therapeutics to Highlight Ex Vivo Genome Editing and CRISPR/Cas9 Manufacturing Advances at ASH

Intellia Therapeutics to Present at ASH Intellia Therapeutics ( NTLA ) announced the presentation of data from its ex vivo research and development efforts in two poster presentations at the 63rd American Society of Hematology ( ASH ) Annual Meeting and Exposition taking place...

November 6, 2021

TCR2 Therapeutics Encouraging Oncology Results

TCR2 Therapeutics Announcement TCR2 Therapeutics ( TCRR ) - a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for cancer, announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2...

July 27, 2020

Immunome Inc Stock Rallied After Announcing it Neutralized the SARS-CoV-2 Delta Variant.

Immunome Inc: Neutralizing SARS-C0V-2 Delta Variant Immunome Inc ( IMNM ) is a small biotech firm whose stock soared after announcing today that its three-antibody cocktail ( IMM-BCP-01 ) demonstrated potent neutralizing activity against the SARS-CoV-2 (the virus that cause...

July 20, 2021

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024